SGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

被引：0
|
作者：
Boni, V. [1 ]
Alemany, C. [2 ]
Meisel, J. L. [3 ]
Sinha, R. [4 ]
Sterrenberg, D. [5 ]
Tkaczuk, K. H. R. [6 ]
Wang, Y. [7 ]
Wang, Z. [8 ]
Han, H. S. [9 ]
机构：
[1] Hosp Univ HM Sanchinarro, Ctr Integral Oncol Clara Campal, Madrid, Spain
[2] Canc Inst Florida, AdventHlth Med Grp, Orlando, FL USA
[3] Winship Canc Inst, Dept Hematol Med Oncol, Atlanta, GA USA
[4] Piedmont Canc Inst, Atlanta, GA USA
[5] Ingalls Mem Hosp, Ingalls Canc Care, Harvey, ND USA
[6] Univ Maryland, Dept Med, Ctr Canc, Greenbaum Comprehens Canc Ctr, Baltimore, MD 21201 USA
[7] Seattle Genet Inc, Biostat, Bothell, WA USA
[8] Seattle Genet Inc, Clin Res, Bothell, WA USA
[9] H Lee Moffitt Canc Ctr & Res Inst, Dept Breast Oncol, Tampa, FL USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
196TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study
    Schmid, P.
    Jung, K. H.
    Wysocki, P. J.
    Jassem, J.
    Ma, C. X.
    Fernandes, R.
    Huisden, R.
    Stewart, R.
    Vukovic, P.
    Nunes, A. Tablante
    Nowecki, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S199 - S199
  • [22] A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
    Brufsky, A.
    Kim, S. B.
    Zvirbule, Z.
    Eniu, A.
    Mebis, J.
    Sohn, J. H.
    Wongchenko, M.
    Chohan, S.
    Amin, R.
    Yan, Y.
    McNally, V
    Miles, D.
    Loi, S.
    ANNALS OF ONCOLOGY, 2021, 32 (05) : 652 - 660
  • [23] Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study
    Schmid, P.
    Wysocki, P. J.
    Ma, C. X.
    Park, H.
    Fernandes, R.
    Lord, S.
    Baird, R. D.
    Prady, C.
    Jung, K. H.
    Asselah, J.
    Huisden, R.
    Stewart, R.
    Heider, K.
    Vukovic, P.
    Denduluri, N.
    Nowecki, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S337 - S337
  • [24] Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
    Shui, Lin
    Cheng, Ke
    Li, Xiaofen
    Shui, Pixian
    Zhou, Xiaohan
    Li, Jian
    Yi, Cheng
    Cao, Dan
    BMC CANCER, 2020, 20 (01)
  • [25] Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
    Lin Shui
    Ke Cheng
    Xiaofen Li
    Pixian Shui
    Xiaohan Zhou
    Jian Li
    Cheng Yi
    Dan Cao
    BMC Cancer, 20
  • [26] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
    Balar, Arjun V.
    Castellano, Daniel
    O'Donnell, Peter H.
    Grivas, Petros
    Vuky, Jacqueline
    Powles, Thomas
    Plimack, Elizabeth R.
    Hahn, Noah M.
    de Wit, Ronald
    Pang, Lei
    Savage, Mary J.
    Perini, Rodolfo F.
    Keefe, Stephen M.
    Bajorin, Dean
    Bellmunt, Joaquim
    LANCET ONCOLOGY, 2017, 18 (11): : 1483 - 1492
  • [27] Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First-Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer
    Musolino, A.
    Bisagni, G.
    De Matteis, A.
    Nuzzo, F.
    Ardizzoni, A.
    Crino, L.
    Gamucci, T.
    Passalacqua, R.
    Gnoni, R.
    Boni, C.
    CANCER RESEARCH, 2010, 70
  • [28] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB PLUS CHEMOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN GREECE
    Yfantopoulos, N.
    Gountas, I
    Athanasopoulos, C.
    Haiderali, A.
    Huang, M.
    Skroumpelos, A.
    Karokis, A.
    VALUE IN HEALTH, 2022, 25 (12) : S184 - S184
  • [29] A multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of YH003 in combination with pembrolizumab and nab-paclitaxel in the first-line treatment of patients with unresectable/metastatic mucosal melanoma
    Chen, Yu
    Zhang, Xiaoshi
    Ding, Ya
    Jiang, Yu
    Chen, Jing
    Pu, Xingxiang
    Ren, Xiubao
    Zhang, Weizhen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] COLET: A multistage, phase 2 study evaluating the safety and efficacy of cobimetinib in combination with paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer
    Kim, S-B
    Miles, D.
    Rhee, J.
    Yan, Y.
    Hsu, J.
    Brufsky, A.
    CANCER RESEARCH, 2016, 76
12345